About: Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Creator	Shyr, Yu Yu, Peter Wu, Yu Shah, Dimpy Stockerl-Goldstein, Keith Bakouny, Ziad Batist, Gerald Bekaii-Saab, Tanios Bilen, Mehmet Bouganim, Nathaniel Castellano, Daniel Choueiri, Toni De, Gilberto Desai, Aakash Doroshow, Deborah Egan, Pamela Elkrief, Arielle Farmakiotis, Dimitrios Flora, Daniel Galsky, Matthew Glover, Michael Griffiths, Elizabeth Grivas, Petros Gulati, Anthony Gupta, Shilpa Hafez, Navid Halfdanarson, Thorvardur Hawley, Jessica Hsu, Chih-Yuan Hsu, Emily Kasi, Anup Khaki, Ali Kuderer, Nicole Larroya, Mateo Lemmon, Christopher Lewis, Colleen Logan, Barbara Lopes, Lima Lyman, Gary Masters, Tyler Mckay, Rana Mesa, Ruben Mishra, Sanjay Morgans, Alicia Mulcahy, Mary Painter, Corrie Panagiotou, Orestis Peddi, Prakash Pennell, Nathan Peters, Solange Prete, Del Reynolds, Kerry Rini, Brian Rivera, Donna Rosen, Lane Rosovsky, Rachel Rubinstein, Samuel Salazar, Mary Schmidt, Andrew Shah, Sumit Shaya, Justin Shete, Sanjay Steinharter, John Subbiah, Suki Thompson, Michael Tsu, Julie Vinh, Donald Warner, Jeremy Wehbe, Firas Weissmann, Lisa Wulff-Burchfield, Elizabeth Xie, Zhuoer Yeh, Albert Zhou, Alice Zubiri, Leyre
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. METHODS: In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing. FINDINGS: Of 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57–76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53–2·21), male sex (1·63, 1·07–2·48), smoking status (former smoker vs never smoked: 1·60, 1·03–2·47), number of comorbidities (two vs none: 4·50, 1·33–15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11–7·18), active cancer (progressing vs remission: 5·20, 2·77–9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79–4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07–0·84) or the US-Midwest (0·50, 0·28–0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality. INTERPRETATION: Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments. FUNDING: American Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1016/s0140-6736(20)31187-9
bibo:pmid	32473681
has license	no-cc
sha1sum (hex)	f07539a4103260e02229342636b9800319611d87
schema:url	https://doi.org/10.1016/s0140-6736%2820%2931187-9
resource representing a document's title	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
has PubMed Central identifier	PMC7255743
has PubMed identifier	32473681
schema:publication	Lancet
resource representing a document's body	covid:f07539a4103260e02229342636b9800319611d87#body_text
is schema:about of	covid:arg/f07539a4103260e02229342636b9800319611d87 named entity 'severe illness' named entity 'COVID-19' named entity 'cancer' named entity 'impact of COVID-19' named entity 'ICU' named entity 'steroids'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software